<code id='746ABE7454'></code><style id='746ABE7454'></style>
    • <acronym id='746ABE7454'></acronym>
      <center id='746ABE7454'><center id='746ABE7454'><tfoot id='746ABE7454'></tfoot></center><abbr id='746ABE7454'><dir id='746ABE7454'><tfoot id='746ABE7454'></tfoot><noframes id='746ABE7454'>

    • <optgroup id='746ABE7454'><strike id='746ABE7454'><sup id='746ABE7454'></sup></strike><code id='746ABE7454'></code></optgroup>
        1. <b id='746ABE7454'><label id='746ABE7454'><select id='746ABE7454'><dt id='746ABE7454'><span id='746ABE7454'></span></dt></select></label></b><u id='746ABE7454'></u>
          <i id='746ABE7454'><strike id='746ABE7454'><tt id='746ABE7454'><pre id='746ABE7454'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:knowledge    - browse:2
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time